市場調査レポート
商品コード
1425247

自己免疫治療の世界市場レポート 2024年

Autoimmune Treatment Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
自己免疫治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

自己免疫治療の市場規模は近年急速に拡大しています。2023年の68億3,000万米ドルから2024年には76億8,000万米ドルへと、CAGR12.4%で拡大します。このような成長は、有病率の上昇、免疫学分野の進歩、遺伝子研究から得られた知見、患者の意識の高まりや支持、規制当局の支援策など、いくつかの要因によるものです。

自己免疫治療市場は、自己免疫疾患を対象とする薬剤の研究開発(R&D)への投資増加により、大きな成長を遂げるものと思われます。R&Dイニシアチブは、新製品やサービスのイノベーションと採用を促進します。具体的には、自己免疫疾患治療薬の研究開発努力により、より精密で低分子、経口活性で、長期投与に耐えうる特性を備えた免疫抑制薬の創出が可能になります。特に、2022年1月、米国の大手製薬会社Eli Lilly and Companyは、研究開発投資を2021年の70億米ドルから2022年には71億9,000万米ドルに引き上げ、売上高に占める研究開発費の割合を24.8%から25.19%に引き上げました。この研究開発投資の急増が、自己免疫治療市場の成長を後押ししています。

2023年の自己免疫治療市場で最大の地域は北米でした。自己免疫治療市場レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の自己免疫治療市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の自己免疫治療市場規模実績と成長、2018~2023年
  • 世界の自己免疫治療市場規模と成長予測、2023~2028年、2033年

第6章 市場セグメンテーション

  • 世界の自己免疫治療市場、製品別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • 消耗品とアッセイキット
  • 機器
  • サービス
  • 世界の自己免疫治療市場、サービスタイプ別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • 相談と診断
  • 治療とモニタリング
  • 創薬
  • 世界の自己免疫治療市場、疾患別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • 関節リウマチ
  • 全身性エリテマトーデス
  • シェーグレン症候群
  • 甲状腺炎
  • 強皮症
  • その他
  • 世界の自己免疫治療市場、エンドユーザー別セグメンテーション、実績と予測、2018~2023年、2023~2028年、2033年
  • 臨床検査室
  • 病院
  • その他

第7章 地域と国の分析

  • 世界の自己免疫治療市場、地域別、実績と予測、2018~2023年、2023~2028年、2033年
  • 世界の自己免疫治療市場、国別、実績と予測、2018~2023年、2023~2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 自己免疫治療市場の競合情勢
  • 自己免疫治療市場の企業プロファイル
    • Abbott Laboratories
    • Amgen Inc.
    • Johnson &Johnson Services Inc.
    • Eli Lilly and Company
    • Pfizer Inc.

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の展望と潜在性分析

第35章 付録

目次
Product Code: r12478

Autoimmune Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on autoimmune treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for autoimmune treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The autoimmune treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Product: Consumables and Assay Kits; Instruments; Services
  • 2) By Service Type: Consultation and Diagnosis; Therapy and monitoring; Drug development
  • 3) By Disease: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Sjogren's Syndrome; Thyroiditis; Scleroderma; Other Diseases
  • 4) By Drug Class: Anti-Inflammatory; Anti-Hyperglycemic; NSAIDs; Interferons; Other Drug Class
  • 5) By End User: Clinical Laboratories; Hospitals; Other End Users
  • Companies Mentioned: Abbott Laboratories; Amgen Inc.; Johnson & Johnson Services Inc.; Eli Lilly and Company; Pfizer Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Autoimmune treatment encompasses the strategic management and support provided to patients to address autoimmune diseases or disorders. In these conditions, the immune system targets the body's own cells. The application of autoimmune treatment aims to effectively address and manage autoimmune diseases.

In the realm of autoimmune treatment, the primary product categories comprise consumables and assay kits, instruments, and services. Consultation denotes the act of seeking guidance from physicians or healthcare professionals for diagnostic studies, therapeutic interventions, or related services. Diagnosis, on the other hand, involves the systematic identification of the nature of an illness or problem through the examination of signs and symptoms. The principal service types encompass consultation and diagnosis, therapy and monitoring, and drug development, with a focus on various diseases such as rheumatoid arthritis, systemic lupus erythematosus, sjogren's syndrome, thyroiditis, scleroderma, among others. Key drug classes integral to autoimmune treatment include anti-inflammatory agents, anti-hyperglycemics, NSAIDs, interferons, and others. Clinical laboratories, hospitals, and similar entities constitute the primary end users in this domain.

The autoimmune treatment market report is one of a series of new reports from The Business Research Company that provides autoimmune treatment statistics, including autoimmune treatment industry global market size, regional shares, competitors with an autoimmune treatment market share, detailed autoimmune treatment market segments, market trends and opportunities, and any further data you may need to thrive in the autoimmune treatment industry. This autoimmune treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The autoimmune treatment market size has grown rapidly in recent years. It will grow from $6.83 billion in 2023 to $7.68 billion in 2024 at a compound annual growth rate (CAGR) of 12.4%. The growth observed in the historical period can be ascribed to several factors, including the rising prevalence of the condition, advancements in the field of immunology, insights gained from genetic research, heightened awareness and advocacy among patients, as well as supportive regulatory measures.

The autoimmune treatment market size is expected to see rapid growth in the next few years. It will grow to $12.64 billion in 2028 at a compound annual growth rate (CAGR) of 13.3%. The anticipated growth in the forecast period can be attributed to the adoption of precision medicine approaches, the emergence of small molecule therapies, the exploration of novel pathways in treatment, innovations in gene therapy, increased investments in biopharmaceuticals, and the expanding biosimilar market. Key trends expected in the forecast period encompass advancements in biologics and targeted therapies, the development of immunomodulatory treatments, a heightened focus on rare autoimmune diseases, the integration of telemedicine and remote monitoring, regulatory initiatives facilitating drug approvals, and the incorporation of digital health tools.

The autoimmune treatment market is set to experience significant growth due to increased investments in research and development (R&D) for drugs targeting autoimmune diseases. R&D initiatives facilitate the innovation and introduction of new products and services. Specifically, R&D efforts in autoimmune disease drugs enable the creation of more precise, low-molecular-weight, orally active, and well-characterized immune suppressive drugs with tolerable long-term treatment profiles. Notably, in January 2022, Eli Lilly and Company, a US-based pharmaceutical giant, raised its R&D investment from $7 billion in 2021 to $7.19 billion in 2022, elevating its R&D expenditure as a percentage of revenue from 24.8% to 25.19%. This surge in R&D investments propels growth within the autoimmune treatment market.

The escalation in healthcare expenditures is poised to drive the growth trajectory of the autoimmune treatment market. Healthcare expenditures encompass all costs associated with delivering health services, including initiatives like family planning, nutrition programs, and emergency health aid, with a focus on overall health improvement. An upsurge in healthcare spending typically leads to the development of more efficient therapies and advancements in medical technologies for treating autoimmune conditions. For instance, according to the American Medical Association in March 2023, healthcare spending in the United States surged by 2.7% to $12,914 per person in 2021, totaling $4.3 trillion. This upward trend in healthcare expenditures is a significant driver fueling growth in the autoimmune treatment market.

Technological advancements emerge as a pivotal trend shaping the landscape of the autoimmune treatment market. Major market players are actively investing in advanced technologies to solidify their positions. Notably, in June 2023, Belgium-based pharmaceutical company UCB received approval from the U.S. Food and Drug Administration (FDA) for RYSTIGGO (rozanolixizumab-noli) to treat generalized myasthenia gravis (gMG) in adults who test positive for anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. This approval, expedited under Priority Review, marks RYSTIGGO as the exclusive FDA-approved therapy for both anti-AchR and anti-MuSK antibody-positive gMG, encompassing the two most prevalent subtypes of this autoimmune condition. This breakthrough signifies a potential enhancement in provider efficiency, treatment efficacy, and overall patient care within the autoimmune illness domain.

Prominent players in the autoimmune treatment market are intensifying their focus on introducing cutting-edge clinical trial platforms as a strategic move to gain a competitive advantage. These innovative platforms in autoimmune treatment capitalize on advanced technologies and personalized methodologies to enhance treatment efficacy, safety, and overall patient outcomes. For instance, in August 2023, the Scleroderma Research Foundation, a US-based non-profit organization, introduced the CONQUEST trial platform. This groundbreaking initiative aims to advance research and therapeutic approaches for scleroderma, a rare autoimmune disease impacting connective tissues. The CONQUEST program addresses pivotal challenges in clinical development, fostering advancements in scleroderma treatment methodologies. Notably, the CONQUEST platform clinical trial represents a pioneering effort in rare autoimmune diseases, specifically focusing on swiftly evaluating potential treatments for interstitial lung disease associated with systemic sclerosis (SSc-ILD) and overall SSc outcomes, encompassing aspects such as skin and other disease manifestations.

In another significant development in August 2023, Eli Lilly and Company, a US-based pharmaceutical giant, completed the acquisition of DICE Therapeutics, Inc. for $2.4 billion. This strategic acquisition expands Lilly's portfolio in the realm of immunology products by integrating DICE's innovative oral therapeutic candidates. Notably, DICE Therapeutics, Inc., a US-based pharmaceutical firm, specializes in developing novel oral therapies targeting autoimmune and inflammatory conditions. Specifically, DICE's oral IL-17 inhibitors, presently undergoing clinical development, are poised to offer innovative treatment approaches for chronic immunological disorders, broadening Lilly's offerings in this therapeutic domain.

Major companies operating in the autoimmune treatment market report are Abbott Laboratories, Amgen Inc., Johnson & Johnson Services Inc., Eli Lilly and Company, Pfizer Inc., Hoffmann-La Roche AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Autoimmune Inc., Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc., Biogen Idec Inc., Bayer Schering Pharma AG, GSK PLC, Genentech Inc., AbbVie Inc., Celgene Corporation, Gilead Sciences Inc., Merck & Co. Inc., Novartis International AG, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB SA, Alexion Pharmaceuticals Inc., Amarin Corporation PLC, AnaptysBio Inc., Apellis Pharmaceuticals Inc., Arena Pharmaceuticals Inc., Aurinia Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company Ltd., BioMarin Pharmaceutical Inc., bluebird bio Inc., Cabaletta Bio Inc., Catabasis Pharmaceuticals Inc., Celsion Corporation, ChemoCentryx Inc., Coherus BioSciences Inc., Corbus Pharmaceuticals Holdings Inc., CRISPR Therapeutics AG, CSL Limited, Cumberland Pharmaceuticals Inc., CytoDyn Inc.

North America was the largest region in the autoimmune treatment market in 2023. The regions covered in the autoimmune treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the autoimmune treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The autoimmune treatment includes revenues earned by entities by providing immunosuppressive therapy, biological treatment, immuno-suppressing medications services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Autoimmune Treatment Market Characteristics

3. Autoimmune Treatment Market Trends And Strategies

4. Autoimmune Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Autoimmune Treatment Market Size and Growth

  • 5.1. Global Autoimmune Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Autoimmune Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Autoimmune Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Autoimmune Treatment Market Segmentation

  • 6.1. Global Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Consumables and Assay Kits
  • Instruments
  • Services
  • 6.2. Global Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Consultation and Diagnosis
  • Therapy and monitoring
  • Drug development
  • 6.3. Global Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Sjogren's Syndrome
  • Thyroiditis
  • Scleroderma
  • Other Diseases
  • 6.4. Global Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Clinical Laboratories
  • Hospitals
  • Other End Users

7. Autoimmune Treatment Market Regional And Country Analysis

  • 7.1. Global Autoimmune Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Autoimmune Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Autoimmune Treatment Market

  • 8.1. Asia-Pacific Autoimmune Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Autoimmune Treatment Market

  • 9.1. China Autoimmune Treatment Market Overview
  • 9.2. China Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Autoimmune Treatment Market

  • 10.1. India Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Autoimmune Treatment Market

  • 11.1. Japan Autoimmune Treatment Market Overview
  • 11.2. Japan Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Autoimmune Treatment Market

  • 12.1. Australia Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Autoimmune Treatment Market

  • 13.1. Indonesia Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Autoimmune Treatment Market

  • 14.1. South Korea Autoimmune Treatment Market Overview
  • 14.2. South Korea Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Autoimmune Treatment Market

  • 15.1. Western Europe Autoimmune Treatment Market Overview
  • 15.2. Western Europe Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Autoimmune Treatment Market

  • 16.1. UK Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Autoimmune Treatment Market

  • 17.1. Germany Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Autoimmune Treatment Market

  • 18.1. France Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Autoimmune Treatment Market

  • 19.1. Italy Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Autoimmune Treatment Market

  • 20.1. Spain Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Autoimmune Treatment Market

  • 21.1. Eastern Europe Autoimmune Treatment Market Overview
  • 21.2. Eastern Europe Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Autoimmune Treatment Market

  • 22.1. Russia Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Autoimmune Treatment Market

  • 23.1. North America Autoimmune Treatment Market Overview
  • 23.2. North America Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Autoimmune Treatment Market

  • 24.1. USA Autoimmune Treatment Market Overview
  • 24.2. USA Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Autoimmune Treatment Market

  • 25.1. Canada Autoimmune Treatment Market Overview
  • 25.2. Canada Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Autoimmune Treatment Market

  • 26.1. South America Autoimmune Treatment Market Overview
  • 26.2. South America Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Autoimmune Treatment Market

  • 27.1. Brazil Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Autoimmune Treatment Market

  • 28.1. Middle East Autoimmune Treatment Market Overview
  • 28.2. Middle East Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Autoimmune Treatment Market

  • 29.1. Africa Autoimmune Treatment Market Overview
  • 29.2. Africa Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Autoimmune Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Autoimmune Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Autoimmune Treatment Market Competitive Landscape
  • 30.2. Autoimmune Treatment Market Company Profiles
    • 30.2.1. Abbott Laboratories
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Amgen Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Johnson & Johnson Services Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Eli Lilly and Company
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Pfizer Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Autoimmune Treatment Market Competitive Benchmarking

32. Global Autoimmune Treatment Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Autoimmune Treatment Market

34. Autoimmune Treatment Market Future Outlook and Potential Analysis

  • 34.1 Autoimmune Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Autoimmune Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Autoimmune Treatment Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer